<i>In-vitro</i> proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report

Taguchi, M.; Tatenuma, Takehiro; Okada, Hironari; Miyazaki, Ryohei; Hirohashi, Kentaro; Kume, Motohiko; Matsusaki, Keisuke; Orihashi, Kazumasa

doi:10.12998/wjcc.v7.i23.4036

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although experience is limited, 10 6 ‐10 7 cancer cells have been collected. They can be used as antigens for producing a dendritic cell vaccine, for anticancer‐drug sensitivity testing, 18 or even for genome‐based drug discovery 8 …”

Section: Discussionmentioning

confidence: 99%

Feasibility, efficacy, and safety of cell‐free and concentrated ascites reinfusion therapy (KM‐CART) for malignant ascites

Matsusaki¹,

Orihashi

2020

Artificial Organs

Self Cite

View full text Add to dashboard Cite

Efficacy for alleviating signs/symptoms of malignant ascites of a renovated CART (cell‐free and concentrated ascites reinfusion therapy) system, called KM‐CART, was evaluated. A total of 4781 KM‐CART procedures were performed in 2109 patients. All patients were accepted unless hemodynamically unstable or consciousness impaired. The ascites were processed and drip‐infused into the patient. There were no major complications or deaths. The mean drainage volume was 6.2 L (maximum: 27.7 L), patient symptoms (numerical scale system) were significantly alleviated (45.1 ± 19.0 reduced to 21.2 ± 14.2, P < .001), and patient leg circumference significantly decreased (33.3 ± 4.4 cm reduced to 30.5 ± 4.4 cm, P < .001) without exacerbation of renal function. Collected cancer cells could be utilized for immune therapy. KM‐CART is capable of improving the “quality of best supportive care” and can be beneficial in conjunction with medication for alleviating malignant pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Feasibility, efficacy, and safety of cell‐free and concentrated ascites reinfusion therapy (KM‐CART) for malignant ascites

Matsusaki¹,

Orihashi

2020

Artificial Organs

Self Cite

View full text Add to dashboard Cite

show abstract

“…2). Furthermore, the backwash function for filtration membrane obstruction has made it possible to treat a large amount of cancerous ascites of 10 L or more (maximum 28 L), and a large amount of cancer cells that can be recovered from the lavage fluid are being used for cancer research and treatment [11][12][13].…”

Section: (3) Cell-free and Concentrated Ascites Reinfusion Therapy (Cart)mentioning

confidence: 99%

Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021)

Matsusaki¹,

Aridome

Emoto

et al. 2021

Int J Clin Oncol

Self Cite

View full text Add to dashboard Cite

Patients with peritoneal dissemination (PD) caused by abdominal malignancies are often associated with massive ascites, which shows extremely dismal prognosis because of the discontinuation of systemic chemotherapy mostly due to poor performance status. Many treatment methods, such as simple drainage, peritoneovenous shunting (PVS) and cell-free and concentrated reinfusion therapy (CART), have been used for symptom relief. However, the clinical efficacies of these methods have not been fully investigated yet. Recently, we developed the Clinical Practice Guideline for PD caused by various malignancies according to "Minds Clinical Practice Guideline Development Guide 2017". In this guideline, we systematically reviewed information on clinical diagnosis and treatments for PD using PubMed databases (2000 – 2020), and clarified the degree of recommendation for clinical questions (CQ). The evidence level was divided into groups by study design and quality. The literature level and a body of evidence were evaluated in reference to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Based on the results of systematic review, the strength of the recommendations was evaluated at a consensus meeting of the Guideline Committee. This is the English synopsis of the part of treatment of malignant ascites in Clinical Practice Guideline for PD, 2021 in Japanese. The guidelines summarize the general aspect of the treatment of malignant ascites and statements with recommendation strengths, evidence levels, agreement rates and future perspective for four raised clinical questions.

show abstract

In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report

Cited by 2 publications

References 22 publications

Feasibility, efficacy, and safety of cell‐free and concentrated ascites reinfusion therapy (KM‐CART) for malignant ascites

Feasibility, efficacy, and safety of cell‐free and concentrated ascites reinfusion therapy (KM‐CART) for malignant ascites

Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021)

Contact Info

Product

Resources

About